BMEA - This Pharma Stock Dropped 60% Premarket As FDA Halted Diabetes Drug Trials | Benzinga
Biomea Fusion, Inc. (NASDAQ:BMEA) saw its stock drop by 60.3% pre-market on Friday after the United States Food and Drug Administration (FDA) imposed a full clinical hold on its Phase I/II trials for BMF-219, a diabetes treatment.
What Happened: The FDA’s decision was driven by concerns over potential drug-induced hepatotoxicity observed during the Dose Escalation Phase of the trials, according to their press release. Elevated liver enzyme levels were noted, although most adverse events were mild to moderate, with no severe reactions reported.
At the time of writing, Biomea Fusion’s stock was trading ...